Various diagnostic tools now a days relied on the Hybriodoma technology and monoclonal antibodies,so this presentation will give some basic information about mAb and Hybridoma technology.
Production and applications of monoclonal antibodiesKaayathri Devi
production and applications of monoclonal antibodies, monoclonal antibodies ,applications of monoclonal antibodies, production of monoclonal antibodies,
Hybridoma technology is a method for producing large number of identical antibodies called monoclonal antibodies.
It was discovered by G.kohler and C.milstein in 1975. they were awarded nobel prize for physiology and medicine in 1975.
The hybrid cells are produced by fusing B- lumphocyte with myeloma cells or tumour cells.
The B-lymphocyte have the ability to produce large number of antibodies and tumour cells have indefinite growth.
This is why two cells are used for the production of hybrid cell
Production and applications of monoclonal antibodiesKaayathri Devi
production and applications of monoclonal antibodies, monoclonal antibodies ,applications of monoclonal antibodies, production of monoclonal antibodies,
Hybridoma technology is a method for producing large number of identical antibodies called monoclonal antibodies.
It was discovered by G.kohler and C.milstein in 1975. they were awarded nobel prize for physiology and medicine in 1975.
The hybrid cells are produced by fusing B- lumphocyte with myeloma cells or tumour cells.
The B-lymphocyte have the ability to produce large number of antibodies and tumour cells have indefinite growth.
This is why two cells are used for the production of hybrid cell
Hybridoma technology is a method for producing large numbers of identical antibodies (also called monoclonal antibodies). This process starts by injecting a mouse (or other mammals) with an antigen that provokes an immune response.
Hybridoma
Hybridomas are cells that have been engineered to produce a desired antibody in large amounts, to produce monoclonal antibodies.
Monoclonal antibodies can be produced in specialized cells through a technique now popularly known as hybridoma technology.
Hybridoma technology was discovered in 1975 by two scientists, G. Kohler and C. Milstein, were awarded Noble prize for physiology and medicine in 1984.
Hybridoma technology is a method for producing large numbers of identical antibodies (also called monoclonal antibodies). This process starts by injecting a mouse (or other mammals) with an antigen that provokes an immune response.
Hybridoma
Hybridomas are cells that have been engineered to produce a desired antibody in large amounts, to produce monoclonal antibodies.
Monoclonal antibodies can be produced in specialized cells through a technique now popularly known as hybridoma technology.
Hybridoma technology was discovered in 1975 by two scientists, G. Kohler and C. Milstein, were awarded Noble prize for physiology and medicine in 1984.
A hybridoma is a hybrid cell obtained by fusion of B lymphocyte with usually a tumor cell of antibody forming system or B lymphocyte (these are called myelomas).
Conceptual Understanding of Monoclonal Bodies Production via Hybirdoma Techno...SindhBiotech
This video is presented by our volunteer Mehwish Khan, she is from Karachi, Pakistan, and she is covering "Monoclonal Bodies Production via Hybirdoma Technology"
for video: https://youtu.be/NilP7HIALvY
#Hybirdoma #antibody #monoclonalantibodies #biology #physiology #health #polyclonalantibody
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
Hybridoma technology revolutionized the field of immunology by enabling the production of monoclonal antibodies with high specificity and affinity. This presentation delves into the principles of DNA hybridoma technology, highlighting its significance in antibody production, therapeutic applications, and biomedical research. Learn about the key steps involved in generating hybridomas, from immunization to antibody screening, and discover the potential of recombinant DNA techniques in enhancing antibody engineering. Whether you're a student, researcher, or industry professional, this overview will provide valuable insights into the innovative world of hybridoma technology."
Uncover the wide-ranging applications of monoclonal antibodies in areas such as cancer therapy, autoimmune diseases, infectious diseases, and beyond. Learn about the latest advancements in antibody engineering and the development of novel therapeutic modalities, including bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors.
Whether you're a seasoned researcher or a newcomer to the field, this SlideShare presentation serves as a valuable resource for understanding the principles, techniques, and applications of hybridoma technology in modern biomedicine. Join a journey through the fascinating world of monoclonal antibodies and the groundbreaking science behind their creation.
Unlock the potential of hybridoma technology and propel your research to new heights. Dive into this SlideShare presentation now and explore the limitless possibilities of monoclonal antibody production with hybridoma technology.
Monoclonal antibodies are been developed an produced from some identical parental immune cells. they can be developed to target and identify specific cells and antigens and to work as antibodies in tandem with the human immune system against them. Hybridoma technology was developed by Georges J.F. Kohler and Cesar Milstein. they made a hybrid cell that will make number of monoclonal antibodies against them.
Topics included :- Introduction to monoclonal antibody; Principle for creation of hybridoma cells and steps involved in it; Second generation monoclonal antibodies; Advantages, disadvantages and applications (Diagnostic and therapeutic) of MAbs.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
2. • First immortal monoclonal Ab’s produced by George
Kohler and Cesar Milstein in 1975
• They shared Nobel prize for this discovery in 1984
• The term Hybridoma was coined by Leonard
Herzenberg in 1975.
3. • ANTIBODY:
It is a soluble globular protein ( Glycoprotein),Which is produced
in response to a specific antigen and binds via non-specific interactions .
The term Immunoglobulin is used to describe any Antibody
regardless of its specificity , whereas Antibody describes ANTIGEN-
SPECIFIC immunoglobulin.
• MONOCLONAL ANTIBODY(MAb) :
Single type of Antibody which is directed against specific type
of antigenic determinant (epitope) is called as monoclonal antibody.
4. MONOCLONAL ANTIBODIES….
• Antibodies produced from a single clone of B cells.
• Produced by fusing a B cell secreting the desired antibody with
a myeloma cell capable of growing indefinitely in tissue culture.
• Monoclonal antibodies all have identical antigen-binding sites.
Thus they all bind to the same epitope with the same affinity.
They are all of the same antibody class (isotype).
5.
6. 1. Murine antibody.
1.Whole of the antibody is of murine origin
Major problems associated with murine
antibodies include
reduced stimulation of cytotoxicity
Formation of complexes after
repeated administration
allergic reactions.
2. Chimeric antibody.
1.Chimeric antibodies are composed of
murine variable regions fused onto human
constant regions.
2.Antibodies are approximately 65%
human.
3.Humanized antibody.
1.Humanized antibodies are produced by
grafting murine hyper variable amino acid
domains into human antibodies.
2.This results in a molecule of approximately
95% human origin
7.
8. HYBRIDOMA TECHNOLOGY
A hybridoma is a hybrid cell obtained by fusion of B lymphocyte with usually a tumor cell of
antibody forming system or B lymphocyte (these are called myelomas)
9. The hybrid cell has the capacity of antibody production derived from B cells
At the same time it can divide continuously by the quality derived from Myeloma cells
By combining the desired qualities of both the cells, the technology ensures large scale
Antibody production of single specificity
Specific hybridomas are either cultured in vitro or passed through mouse peritoneal cavity
to obtain monoclonal antibodies, this is called as hybridoma technology
PRINCIPLE
10. 1.Isolation of B cells
-Mice , 2-4 weeks old are immunized with the antigen against which monoclonal antibodies are
to be raised by subcutaneous injection
-Later B cells are isolated from the spleen of an immunized mouse
2.Isolation of myeloma cells
-Myeloma cells are isolated from bone marrow
-The myeloma cells used are HGPRT(Hypoxanthine-guanine phosphoribosyl transferase) mutant
cells ( raised by mutations using 8-azaguanine)
STEPWISE PROCEDURE
11. • This Cell Line Is Deficient In HGPRT (hypoxantine guanine
phosphoribosyl transferase)
• Alternatively TK (thymidine kinase deficient)
• Cell Line Cannot Survive In Selection Medium
• Aminopterin Inhibits “De novo Pathway”, “Salvage Pathway” Is Not
Possibe Due To HGPRT or TK Deficiency
• It Is Also Ig Deficient
• It can not secret any immunoglobulins
• Aminopterin (folic acid antagonist) Blocks De novo Pathway
• P3.653 cells die in the presence of aminopterin
• They cannot utilize the “salvage pathway” because they are HGPRT
deficient
P3.653 MYELOMA
12. Somatic cell fusion
-Electrofusion : cells are allowed to fuse with the application of an electric field
-Done by using PEG medium
-PEG stands for Poly Ethylene Glycol
The New Hybrid Cell Exhibits Properties Of Both Cell Types
Unlimited growth
Secretes monoclonal antibody
Or Secretes cytokines
13.
14.
15.
16. Selection of hybrid cells
-HAT medium is used for the selection of hybrid cells
-HAT stands for Hypoxanthine Aminopterine Thymidine
Nucleotide synthesis is essential for cell survival
In HAT medium, aminopterine blocks the cellular synthesis of purines and
pyramidines from simple sugars (denovo pathway)
But cells can succeed by using hypoxanthine and thymidine present in the
medium by salvage pathway using the enzyme HGPRT
17. -B cells are HGPRT+ and can survive in the HAT medium, but they undergo normal cell death after
some division
- In hybridoma technology, the myeloma cells used are HGPRT deficient
-So these cells can’t survive in HAT medium as Aminopterine blocks the Denovo pathway
Hybrid cells has HGPRT enzyme from the B cell as well as they have the ability to multiply repeatedly
as myeloma cells
So only hybrid cells can survive in HAT medium
HOW HAT MEDIUM WORKS IN THE SELECTION OF HYBRID
CELLS?
18.
19.
20. IDENTIFICATION AND ISOLATION OF THE
HYBRIDOMA CELLS
• • The first screening technique used is ELISA
• -Done by incubating the hybridoma culture supernatant, secondary enzyme labeled
conjugate and chromogenic substrate
• -Formation of a coloured product indicates a positive hybridoma
21. 1.Diagnostic Applications.
A. Biochemical analysis.
B. Diagnostic
imaging(immunoscintigraphy).
2. Therapeutics
A. Direct Agent.
B. Targeting Agent
3. Protein purification
Others..
Eg.
Abzymes
APPLICATIONS
OF MONOCLONAL
ANTIBODIES
22. DIAGNOSTIC APPLICATIONS
A. Biochemical
Analysis
B.Diagnositic
imaging
Eg. HIV test
Generally used
Radioisotopes are Iodine
131, technetium 99, Indium
chloride 111.
1. Radiolabel
the specific
monoclonal
antibody.
2. Inject them
intravenously into
the patients.
3. Detection by
using
SPECT(Single
Photon Emission
computed
tomography).
Used in detection of cancer, Bacterial
infections , Heart attack etc.
23. Metastatic medullary Thyroid carcinoma .
Patient was injected with Anti-CEA bispecific antibody with
indium111, and immunoscintigaphy was performed after 4
days. Liver , Bone and Brain shows good uptake of labelled
Antibody which shows metastatic tumour.
24. Therapeutics
1.Direct 2.Targeting agents
Eg . As
immunosupres
ent in organ
transplants.
OKT3
monoclonal
antibody
specifically
directed
against CD3
antigen of T
lymphocyte.
The toxins can
be coupled with
MAb’s to form
immunotoxins
.Anti –IL2-R
conjugated with
exotoxin of
Pseudomonas
sp. Can be used
to destroy
malignant T cells
of T cell leukemia
Some drugs
,
radioisotope
s can be also
attached to
MAb’s and
carried out
towards the
specific
tissue for
efficient
actions